A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity

Background: A broad, robust, and long-lasting antibody response is essential for effective anti-SARS-CoV-2 immunity and the prevention of breakthrough infections. As a key member of the tumor necrosis factor superfamily, a proliferation-inducing ligand (APRIL) participates in multiple B cell fate processes, including B cell survival, class-switch recombination, and plasma cell (PC) differentiation, but its potential utility as a SARS-CoV-2 vaccine adjuvant remains largely unexplored. Methods: Balb/c mice were immunized with recombinant XBB.1.5 S protein formulated with alum, with or without the addition of APRIL. Serum, bronchoalveolar lavage fluid (BALF), and fecal samples were collected for measuring antigen-specific IgG/IgA titers and antibody avidity by ELISA. Neutralization against Delta, BA.2.12.1, BF.7, XBB.1.5, and JN.1 was determined in HEK293-ACE2 cells, while cellular responses were assessed by flow cytometry and Enzyme-Linked Immunospot (ELISPOT). Gene expressions were quantified by RT-PCR. Results: APRIL augmented the immunogenicity of XBB.1.5 S in a dose-dependent manner. It promoted the generation of both systemic and mucosal antibodies, broadened the binding breadth and avidity, and conferred superior neutralizing activity against multiple variants. During a 20-week post-immunization monitoring period, mice maintained effective antibody titers and retained the capacity to neutralize diverse variants. Mechanistically, APRIL was associated with upregulated AICDA and UNG mRNA expressions, accompanied by expansion of the B cell repertoire, differentiation into PCs and antigen-specific memory B cells, and maintenance of high-avidity long-lived PCs. Conclusions: APRIL acts as an effective adjuvant that elicits broad-spectrum, long-lasting immunity against SARS-CoV-2 variants. It represents a promising immunostimulatory component for optimizing the performance of recombinant spike protein vaccines.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-11-13
DOI
https://doi.org/10.3390/vaccines14110976
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity

BingXiang Li, Hongye Wang, You Yang, Xiaoyong Zhu et al.
5 links
Vaccines
SARS-CoV-2 and COVID-19 Research
article

A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity

BingXiang Li, Hongye Wang, You Yang, Xiaoyong Zhu, Cheng Chen, Zijie Zhang, Yufeng Yao, Rui Cheng, Xinyu Jiang, Xinwen Guo, Huan Yang, Ming Sun
article en

Abstract

Background: A broad, robust, and long-lasting antibody response is essential for effective anti-SARS-CoV-2 immunity and the prevention of breakthrough infections. As a key member of the tumor necrosis factor superfamily, a proliferation-inducing ligand (APRIL) participates in multiple B cell fate processes, including B cell survival, class-switch recombination, and plasma cell (PC) differentiation, but its potential utility as a SARS-CoV-2 vaccine adjuvant remains largely unexplored. Methods: Balb/c mice were immunized with recombinant XBB.1.5 S protein formulated with alum, with or without the addition of APRIL. Serum, bronchoalveolar lavage fluid (BALF), and fecal samples were collected for measuring antigen-specific IgG/IgA titers and antibody avidity by ELISA. Neutralization against Delta, BA.2.12.1, BF.7, XBB.1.5, and JN.1 was determined in HEK293-ACE2 cells, while cellular responses were assessed by flow cytometry and Enzyme-Linked Immunospot (ELISPOT). Gene expressions were quantified by RT-PCR. Results: APRIL augmented the immunogenicity of XBB.1.5 S in a dose-dependent manner. It promoted the generation of both systemic and mucosal antibodies, broadened the binding breadth and avidity, and conferred superior neutralizing activity against multiple variants. During a 20-week post-immunization monitoring period, mice maintained effective antibody titers and retained the capacity to neutralize diverse variants. Mechanistically, APRIL was associated with upregulated AICDA and UNG mRNA expressions, accompanied by expansion of the B cell repertoire, differentiation into PCs and antigen-specific memory B cells, and maintenance of high-avidity long-lived PCs. Conclusions: APRIL acts as an effective adjuvant that elicits broad-spectrum, long-lasting immunity against SARS-CoV-2 variants. It represents a promising immunostimulatory component for optimizing the performance of recombinant spike protein vaccines.

VaccinesVol. 14(11)
Yunnan University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon